拉米夫定联合阿德福韦酯抗病毒治疗在乙肝肝硬化患者中的应用效果

Abstract
Figure/Table
References (15)
Related Citation (14)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effect of antiviral therapy in hepatitis B cirrhosis.Methods According to the randomized method,60 patients with hepatitis B cirrhosis were diagnosed and treated in our hospital from February 2015 to March 2017.They were equally divided into control group and observation group,30 cases in each group.In the control group,routine symptomatic treatment and Lamivudine were used,while in the observation group,Lamivudine Plus combined with Adefovir Dipivoxil as antiviral therapy was adopted.The effect of the two groups were compared.Results The total effectiveness rate of hepatitis B liver cirrhosis in the observation group was significantly higher than that of the control group (P<0.05）.The Child-Pugh score and prothrombin activity in the observation group were significantly higher than those in the control group （P<0.05）.HBV-DNA in the observation group was significantly lower than that in the control group （P<0.05）.There was no significant difference between the two groups before the intervention of PCⅢ,IVC,LN,or HA （P＞0.05）.The changes of differences in liver fibrosis indexes such as PCⅢ,IVC,LN,and HA in the observation group were significantly lower than those in the control group after intervention （P<0.05）.Besides,the changes of these indexes above-mentioned in the two groups after intervention were significantly lower than those before intervention,which were displayed statistical significance （P<0.05）.Conclusion Lamivudine combined with Adefovir Dipivoxil as anti-virus is effective in the treatment of hepatitis B cirrhosis.The clinical effect is reliable.It can remarkably alleviate the hepatic fibrosis,increase the activity of prothrombin,and reduce HBV-DNA.

Key words： Hepatitis B cirrhosis Anti-virus Adefovir dipivoxil

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Guo-bin
	HUANG Rong-wang
	WEI Di
	CHEN Ming

Cite this article:

LI Guo-bin,HUANG Rong-wang,WEI Di, et al. Application effect of antiviral therapy with Lamivudine combined with Adefovir Dipivoxil in patients with hepatitis B cirrhosis[J]. 中国当代医药, 2018, 25(20): 43-45.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I20/43

[1]	苟卫，王燕玲，徐筱玮，等.恩替卡韦治疗乙型肝炎肝硬化合并肝源性糖尿病的临床观察[J].临床肝胆病杂志，2013，29（6）：456-458.
[2]	陈春娇，周晶.恩替卡韦治疗乙型肝炎肝硬化伴肝源性糖尿病的临床应用效果[J].中国生化药物杂志，2017，37（10）：213-214.
[3]	李云静.阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效及安全性评价[J].实用药物与临床，2012，15（12）：822-824.
[4]	武玲，武德廉.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的疗效观察[J].蚌埠医学院学报，2012，37（2）：186-188.
[5]	郭诊利.抗病毒治疗乙型肝炎肝硬化伴肝源性糖尿病的临床疗效观察[J].中国当代医药，2012，19（3）：28-29.
[6]	万继红，段红岩，范海威.拉米夫定和阿德福韦酝初始联合抗病毒治疗乙型肝炎肝硬化失代偿期临床观察[J].中国卫生产业，2013，10（9）：63.
[7]	孙建慧.肝硬化并发肝源性糖尿病患者的观察及护理[J].中国实用护理杂志，2012，28（7）：35-36.
[8]	宋宁，贾继东.2011年肝病领域的重要进展[J].中华肝脏病杂志，2012，20（6）：401-404.
[9]	余佳平.乙型肝炎肝硬化失代偿期患者抗病毒治疗的疗效观察[J].肝脏，2013，18（2）：132-133.
[10]	伍灵南，罗林，龙云升.乙型肝炎后肝硬化患者抗病毒治疗疗效及生存质量评价[J].白求恩医学杂志，2014，12（1）：18-19.
[11]	王彩荣，郑皓.乙肝肝硬化抗病毒治疗的疗效观察[J].内蒙古中医药，2013，32（21）：51-52.
[12]	刘爱兵，李宗军，何新明，等.阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化失代偿期的临床疗效[J].重庆医学，2015，44（34）：4812-4814.
[13]	魏兆勇，张分明，许德军，等.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化临床观察[J].中华医院感染学杂志，2014，24（2）：361-363.
[15]	顾而立，姚光弼，王虹，等.阿德福韦酯和拉米夫定联合治疗乙型肝炎相关性代偿期肝硬化96周的有效性和安全性[J].中华消化杂志，2014，34（27）：467-472.